Kitahashi Tsukasa, Takahashi Mami, Yamada Yutaka, Oghiso Yoichi, Yokohira Masanao, Imaida Katsumi, Tsutsumi Masahiro, Takasuka Nobuo, Sugimura Takashi, Wakabayashi Keiji
Cancer Prevention Basic Research Project, National Cancer Center Research Institute, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan.
Cancer Sci. 2008 Feb;99(2):241-5. doi: 10.1111/j.1349-7006.2008.00680.x.
Epidermal growth factor receptor (EGFR) gene alterations have been found in human lung cancers. However, there is no information on the factors inducing EGFR mutations. In rodents, K-ras mutations are frequently found in many lung carcinogenesis models, but hitherto, Egfr mutations have not been reported. Their presence was therefore investigated in representative lung carcinogenesis models with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), N-nitrosobis(2-hydroxypropyl)amine (BHP), 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) and ethyl carbamate (urethane), as well as X-ray irradiation. With the chemical carcinogenesis models, no mutations were detected in Egfr, which is in clear contrast to the high rates observed in either codon 12 or 61 of K-ras (21/23 of the lung tumors induced with NNK, 4/5 with MeIQx, 1/4 with urethane and 7/18 with BHP). However, in the X-ray-induced lung tumors, Egfr mutations with amino acid substitution were observed in exons 18 and 21 (4/12, 33%), but no activating mutation of K-ras was detected. In addition, one and four silent mutations were identified in K-ras (exon 1) and Egfr (exons 18, 20 and 21), respectively. Most mutations in both Egfr and K-ras were G/C-->A/T transitions (7/8, 88% and 31/34, 91%, respectively). Although, the mutational patterns in equivalent human lesions were not completely coincident, this first report of Egfr mutations in an experimental lung tumor model suggests that X-rays or other factors producing oxygen radicals could cause EGFR mutations in some proportion of lung cancers in humans.
在人类肺癌中已发现表皮生长因子受体(EGFR)基因改变。然而,关于诱导EGFR突变的因素尚无相关信息。在啮齿动物中,K-ras突变在许多肺癌发生模型中经常被发现,但迄今为止,尚未报道过Egfr突变。因此,研究人员在具有代表性的肺癌发生模型中对其存在情况进行了研究,这些模型采用了4-(甲基亚硝胺基)-1-(3-吡啶基)-1-丁酮(NNK)、N-亚硝基双(2-羟丙基)胺(BHP)、2-氨基-3,8-二甲基咪唑并[4,5-f]喹喔啉(MeIQx)和氨基甲酸乙酯(尿烷),以及X射线照射。在化学致癌模型中,未检测到Egfr突变,这与在K-ras密码子12或61中观察到的高突变率形成鲜明对比(NNK诱导的肺肿瘤中有21/23发生突变,MeIQx诱导的有4/5,尿烷诱导的有1/4,BHP诱导的有7/18)。然而,在X射线诱导的肺肿瘤中,在外显子18和21中观察到了有氨基酸替换的Egfr突变(4/12,33%),但未检测到K-ras激活突变。此外,分别在K-ras(外显子1)和Egfr(外显子18、20和21)中鉴定出1个和4个沉默突变。Egfr和K-ras中的大多数突变都是G/C→A/T转换(分别为7/8,88%和31/34,91%)。虽然,在等效人类病变中的突变模式并不完全一致,但在实验性肺肿瘤模型中首次报道的Egfr突变表明,X射线或其他产生氧自由基的因素可能在一定比例的人类肺癌中导致EGFR突变。